Ionis Pharmaceuticals (IONS) Total Current Liabilities (2009 - 2026)

Ionis Pharmaceuticals' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $716.6 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 186.3% year-over-year to $716.6 million; the TTM figure through Mar 2026 stood at $716.6 million (up 186.3% YoY), while the FY2025 annual figure was $781.6 million, up 152.67% from the prior year.
• Total Current Liabilities was $716.6 million for Q1 2026 at Ionis Pharmaceuticals, down from $781.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $903.5 million in Q3 2025 to a low of $228.4 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $428.7 million across 5 years, with a median of $309.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities slumped 30.97% in 2024, then jumped 196.64% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $311.6 million in 2022, then soared by 43.82% to $448.1 million in 2023, then plunged by 30.97% to $309.3 million in 2024, then surged by 152.67% to $781.6 million in 2025, then declined by 8.31% to $716.6 million in 2026.
• The last three Total Current Liabilities figures came in at $716.6 million (Q1 2026), $781.6 million (Q4 2025), and $903.5 million (Q3 2025), per Business Quant data.